- Home
- TVTX
as 07-26-2024 4:00pm EST
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.
Upcoming Earnings Alert:
Get ready for potential market movements as Travere Therapeutics Inc. TVTX prepares to release earnings report on 01 Aug 2024.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 558.0M | IPO Year: | N/A |
| Target Price: | $15.36 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.13 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.12 - $17.57 | Next Earning Date: | 08-01-2024 |
| Revenue: | $183,225,000 | Revenue Growth: | 28.61% |
| Revenue Growth (this year): | 52.08% | Revenue Growth (next year): | 49.88% |
Stock Insider Trading Activity of Travere Therapeutics Inc. (TVTX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Cline Christopher R. | TVTX | CHIEF FINANCIAL OFFICER | Apr 11 '24 | Sell | $6.74 | 54 | $363.96 | 70,849 | SEC Form 4 |
| Heerma Peter | TVTX | CHIEF COMMERCIAL OFFICER | Jan 31 '24 | Sell | $8.53 | 4,195 | $35,788.80 | 99,503 | SEC Form 4 |
| Dube Eric M | TVTX | CHIEF EXECUTIVE OFFICER | Jan 31 '24 | Sell | $8.53 | 9,106 | $77,693.30 | 360,616 | SEC Form 4 |
| Dube Eric M | TVTX | CHIEF EXECUTIVE OFFICER | Jan 31 '24 | Sell | $8.86 | 10,016 | $88,741.76 | 350,600 | SEC Form 4 |
| ROTE WILLIAM E. | TVTX | SENIOR VICE PRESIDENT, R&D | Jan 31 '24 | Sell | $8.53 | 2,174 | $18,547.70 | 83,310 | SEC Form 4 |
| ROTE WILLIAM E. | TVTX | SENIOR VICE PRESIDENT, R&D | Jan 31 '24 | Sell | $8.86 | 2,590 | $22,947.40 | 80,720 | SEC Form 4 |
| Calvin Sandra | TVTX | SVP, CHIEF ACCOUNTING OFFICER | Jan 31 '24 | Sell | $8.53 | 2,820 | $24,057.98 | 52,017 | SEC Form 4 |
| REED ELIZABETH E | TVTX | SVP, GC & CORPORATE SECRETARY | Jan 31 '24 | Sell | $8.53 | 2,174 | $18,547.92 | 78,860 | SEC Form 4 |
| REED ELIZABETH E | TVTX | SVP, GC & CORPORATE SECRETARY | Jan 31 '24 | Sell | $8.86 | 2,590 | $22,947.40 | 76,270 | SEC Form 4 |
| Inrig Jula | TVTX | CHIEF MEDICAL OFFICER | Jan 31 '24 | Sell | $8.53 | 2,174 | $18,546.61 | 58,074 | SEC Form 4 |
| Cline Christopher R. | TVTX | CHIEF FINANCIAL OFFICER | Jan 31 '24 | Sell | $8.53 | 3,818 | $32,572.50 | 70,903 | SEC Form 4 |
| REED ELIZABETH E | TVTX | SVP, GC & CORPORATE SECRETARY | Jan 23 '24 | Sell | $8.96 | 2,062 | $18,475.52 | 56,034 | SEC Form 4 |
| Cline Christopher R. | TVTX | CHIEF FINANCIAL OFFICER | Jan 23 '24 | Sell | $9.07 | 853 | $7,735.35 | 49,721 | SEC Form 4 |
| Calvin Sandra | TVTX | SVP, CHIEF ACCOUNTING OFFICER | Jan 23 '24 | Sell | $9.07 | 910 | $8,252.24 | 41,337 | SEC Form 4 |
| Heerma Peter | TVTX | CHIEF COMMERCIAL OFFICER | Jan 23 '24 | Sell | $9.07 | 1,559 | $14,137.64 | 78,698 | SEC Form 4 |
| Dube Eric M | TVTX | CHIEF EXECUTIVE OFFICER | Jan 23 '24 | Sell | $8.96 | 7,873 | $70,542.08 | 234,722 | SEC Form 4 |
| ROTE WILLIAM E. | TVTX | SENIOR VICE PRESIDENT, R&D | Jan 23 '24 | Sell | $8.96 | 2,062 | $18,475.52 | 60,484 | SEC Form 4 |
| Inrig Jula | TVTX | Chief Medical Officer | Jan 3 '24 | Sell | $9.48 | 2,069 | $19,612.88 | 35,688 | SEC Form 4 |
| Inrig Jula | TVTX | Chief Medical Officer | Jan 3 '24 | Sell | $9.17 | 440 | $4,034.80 | 35,248 | SEC Form 4 |
Latest Travere Therapeutics Inc. News
TVTX Breaking Stock News: Dive into TVTX Ticker-Specific Updates for Smart Investing
GlobeNewswire
a day ago
Travere Therapeutics to Report Second Quarter 2024 Financial Results
GlobeNewswire
18 days ago
Travere Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference
Simply Wall St.
a month ago
Shareholders in Travere Therapeutics (NASDAQ:TVTX) are in the red if they invested five years ago
GlobeNewswire
a month ago
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
2 months ago
Intermediate Capital Group plc: Notification of Transactions of Directors
ACCESSWIRE
2 months ago
Argus Research Updated Equity Report Coverage On Tego Cyber Inc.
Yahoo Finance Video
2 months ago
Lyft stock earns multiple upgrades after investor day
Engadget
2 months ago
Finally, I can make my iPhone look like total crap
Compare TVTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TVTX Travere Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.